<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6156">
  <stage>Registered</stage>
  <submitdate>24/08/2016</submitdate>
  <approvaldate>24/08/2016</approvaldate>
  <nctid>NCT02880956</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease</studytitle>
    <scientifictitle>A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001634-10</secondaryid>
    <secondaryid>M15-566</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABBV-8E12
Treatment: drugs - placebo for ABBV-8E12

Experimental: Group 1 - Dose 1 ABBV-8E12

Experimental: Group 2 - Dose 2 ABBV-8E12

Experimental: Group 3 - Dose 3 ABBV-8E12

Placebo Comparator: Group 4 - Placebo for ABBV-8E12


Treatment: drugs: ABBV-8E12
ABBV-8E12 (20 mg/mL) solution for IV infusion

Treatment: drugs: placebo for ABBV-8E12
placebo solution for IV infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Dementia Rating - Sum of Boxes (CDR-SB) - A scale used to quantify the severity of symptoms of dementia.</outcome>
      <timepoint>Week 96</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse Events</outcome>
      <timepoint>112 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed serum concentration (Cmax) for ABBV-8E12</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Cmax (Tmax) for ABBV-8E12</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration time curve (AUC) for ABBV-8E12</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mini-Mental State Examination (MMSE) - A 30-point questionnaire that provides a quantitative measure of cognitive mental status in adults.</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) - A scale that assesses the cognitive impairments most common in AD.</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeatable Battery for Assessment of Neuropsychological Status (RBANS) - A standardized neurocognitive battery that measures cognitive decline or improvement across five neurocognitive domains.</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients with Mild Cognitive Impairment (ADCS-MCI-ADL-24) - A 24-item, study partner-based assessment of activities of daily living designed specifically for AD patients.</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Activities Questionnaire (FAQ) - A questionnaire used to measure level of assistance (functional disability) needed for carrying out instrumental activities in daily living.</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief) - A performance-based instrument which uses a series of tasks and role-play scenarios to evaluate a person's functional capacity in two areas of basic living skills (i.e., financial skills and communication skills).</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI). - The instrument assesses the physician's global impression of change four major cognitive domains.</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject who meets the National Institute on Aging and the Alzheimer's Association
             (NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:

               -  Clinical Dementia Rating (CDR)-Global Score of 0.5

               -  Mini-Mental State Examination (MMSE) score of 22 to 30, inclusive

               -  Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory
                  Index (RBANS - DMI) score of 85 or lower

          -  Subject has a positive amyloid Positron Emission Tomography (PET) scan.

          -  Subject has a Modified Hachinski Ischemic Scale (MHIS) score of = 4.

          -  The subject has an identified, reliable, study partner (e.g., family member).

          -  If using medications to treat symptoms related to AD, doses must be stable for at
             least 12 weeks prior to randomization.</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has any contraindications or inability to tolerate to brain magnetic resonance
             imaging (MRI), PET scans or lumbar puncture.

          -  Subject has evidence of any other clinically significant neurological disorder other
             than Early AD.

          -  In the opinion of the investigator, the subject has any clinically significant or
             uncontrolled medical or psychiatric illness, or has had an infection requiring medical
             intervention in the past 30 days.

          -  Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic
             attack or required intervention for any of these conditions within 6 months of
             Screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>17/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>7/04/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>St VincentÂ´s Hospital /ID# 152632 - Darlinghurst</hospital>
    <hospital>Griffith University /ID# 152635 - Eastwood</hospital>
    <hospital>Australian Alzheimer's Research Foundation /ID# 152634 - Nedlands</hospital>
    <hospital>Neurodegenerative Disorders Research Pty Ltd /ID# 152826 - West Perth</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>4222 - Eastwood</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6005 - West Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early
      Alzheimer's Disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02880956</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hana Florian, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AbbVie_Call Center</name>
      <address />
      <phone>847-283-8955</phone>
      <fax />
      <email>abbvieclinicaltrials@abbvie.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>